Результаты поиска

Clinical characteristics of Mycoplasma pneumoniae pneumonia in children with atopic constitution and risk factors for disease severity: a retrospective comparative study.

OBJECTIVE: To compare the clinical characteristics and immune-inflammatory markers between Mycoplasma pneumoniae pneumonia children with and without atopic constitution, and to identify independent risk factors for severe MPP within the atopic group. METHODS: We retrospectively analyzed the medical records of 377 children diagnosed with MPP at Wuhan Children's Hospital between January 1, 2019, and December 31, 2024, who underwent allergen-specific immunoglobulin E (sIgE) testing for both inhalant and food allergens. The children were divided into two groups based on their atopic constitution:

Совпадение в полном тексте источника
… Poddighe D, Virginia CE, Brambilla I, Licari A, Bruni P, Luigi MG. “Increased total serum immunoglobulin E in children developing Mycoplasma pneumoniae-related extra-pulmonary diseases.”. Iran J Allergy, Asthma Immunol. (2018) 17:490–6. 21. Poddighe D, Marseglia GL. …

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study.

BackgroundPatients with hematological cancer who experience relapse or progressive disease often face yet another line of treatment and continued mortality risk that could increase their physical and emotional trauma and worsen their health-related quality of life. Healthcare professionals who use patient-reported outcomes to identify who will have specific sensitivities in particular health-related quality of life domains may be able to individualize and target treatment and supportive care, both features of precision medicine. Here, in a cohort of patients with relapsed or progressive hemato

Совпадение в полном тексте источника
… The world health organization classification-of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13(2):193–207. doi: 10.1038/modpathol.3880035. 2. …

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recruitment of T cells and CD16a for NK cells. The first T cell engager (the anti-CD19 blinatumomab) was approved by the FDA in 2014, but no other one hit the market until 2022. Now the field is gaining momentum, with three approvals in 2022 and 2023 (as of May): the anti-CD20 × anti-CD3 mosunetuzumab and epcoritamab and the anti-B cell maturation antigen (BCMA) × anti-CD3 teclistamab, and anot

Совпадение в полном тексте источника
… Biosciences ISB 1342 BEAT 1.0 CD38/CD3 MM NCT03309111 1 Ichnos Sciences Y150 YBODY (scFv-Fab-Fc) CD38/CD3 MM NCT05011097 1 Wuhan YZY Biopharma XmAb18968 Bispecific Fc domains CD38/CD3 AML, T-ALL, T-LBL NCT05038644 1 IST SLAMF7 BATs Chemically Hetero-conjugated SLAMF7/CD3 MM NCT04864522 1 University of Virginia … NCT03309111 | 1 | Ichnos Sciences Y150 | YBODY (scFv-Fab-Fc) | CD38/CD3 | MM | NCT05011097 | 1 | Wuhan YZY Biopharma XmAb18968 | Bispecific Fc domains | CD38/CD3 | AML, T-ALL, T-LBL | NCT05038644 | 1 | IST SLAMF7 BATs | Chemically Hetero-conjugated | SLAMF7/CD3 | MM | NCT04864522 | 1 | University of Virginia …

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Mineral Density in the Lumbar Spine Avani Vaishnav 1 , Philip Louie 2 , Chirag Chaudhary 1 , Michael McCarthy 3 , Ryan Lee 4 , Yoshihiro Katsuura 1 , Sravisht Iyer 1 , Steven McAnany 1 , Todd Albert 1 , Catherine Himo Gang 1 , and Sheeraz Qureshi 1 1 Hospital for Special Surgery, New York, USA 2 Virginia …

Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study.

While nurses report challenges with the manual administration of large-volume subcutaneous drugs, these challenges and potential solutions are not captured in the literature. In this cross-sectional study, 45 nurses with experience administering large-volume subcutaneous biologics completed an 18-item survey about preferences for syringes vs. on-body delivery systems. 100% responded that an on-body delivery system seemed easy to learn and use and preferable to syringes. In a drug delivery scenario including comprehensive administration details and assuming equivalent safety and efficacy, 97.78

Совпадение в полном тексте источника
… United States (6 in Illinois; 5 in Georgia; 4 in North Carolina; 3 each in California, Maryland, and Massachusetts; 2 each in Colorado, Florida, Minnesota, New York, and Ohio; and 1 each in Arizona, Kentucky, Michigan, Missouri, New Hampshire, New Jersey, Pennsylvania, South Carolina, Texas, Utah, and Virginia …

A Preliminary Investigation towards the Risk Stratification of Allogeneic Stem Cell Recipients with Respect to the Potential for Development of GVHD via Their Pre-Transplant Plasma Lipid and Metabolic Signature.

The clinical outcome of allogeneic hematopoietic stem cell transplantation (SCT) may be influenced by the metabolic status of the recipient following conditioning, which in turn may enable risk stratification with respect to the development of transplant-associated complications such as graft vs. host disease (GVHD). To better understand the impact of the metabolic profile of transplant recipients on post-transplant alloreactivity, we investigated the metabolic signature of 14 patients undergoing myeloablative conditioning followed by either human leukocyte antigen (HLA)-matched related or unr

Совпадение в полном тексте источника
… Patients Patients were enrolled prospectively in a Virginia Commonwealth University (VCU) Institutional Review Board (IRB)-approved observational pilot study; patients provided written informed consent prior to enrollment (Ethical code: 45 CFR 46.108(b) and 45 CFR 46.109(e) and 45 CFR 46.110 by VCU …

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.

BackgroundInteractions between the protein synthesis inhibitor homoharringtonine (HHT) and the proteasome inhibitor bortezomib were investigated in DLBCL and mantle cell lymphoma cells (MCL).MethodsVarious DLBCL and MCL cells were exposed to HHT and bortezomib alone or together after which apoptosis and signaling pathway perturbations were monitored by flow cytometry and Western blot analysis. Xenograft mouse models were used to assess tumor growth and animal survival.ResultsHHT and bortezomib co-administration synergistically induced apoptosis in GC-, ABC- and double-hit DLBCL cells. Similar

Совпадение в полном тексте источника
… Ethics approval and consent to participate This study was approved by the ethics committee of Virginia Commonwealth University (VCU). Patients signed a written informed consent form. …

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment, or idiotype (Id), linked to fragment C (FrC) of tetanus toxin. Patients in complete or partial response following high-dose chemotherapy and autologous stem cell transplant were vaccinated intramuscularly with 1 mg DNA on six occasions, beginning at least 6 months post-transplant; follow-up was to week 52. Fourteen patients were enrolled on study

Совпадение в полном тексте источника
… Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol. 1999;10:1419–1432. doi: 10.1023/A:1008375931236. 25. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. …

Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells.

BackgroundDespite significant therapeutic advances, multiple myeloma (MM) remains incurable in most patients due to frequent tumor relapse. A major contributor to relapse is clonal heterogeneity, where subclones exhibit distinct mechanisms of therapy resistance, along with the presence of drug-resistant dormant cells. Eliminating these distinct populations, which often coexist in the tumor niche, is clinically challenging. Identifying survival mechanisms shared by drug-resistant proliferating and dormant cells holds potential for the simultaneous elimination of different tumor-repopulating clo

Совпадение в полном тексте источника
… Steven Grant (Virginia Commonwealth University, VA, USA) [ 17 ]. MM cell lines were cultured as previously described and authenticated for proper morphology, surface markers, and paraprotein production [ 10 , 18 ]. …

Latent profile analysis of fear of progression in Chinese hematologic malignancy survivors.

Fear of disease progression (FoP) is a multidimensional concept that refers to the fear or worry about disease progress. Little is known about the distinct FoP profiles and their determinants in culturally specific contexts, especially among hematologic malignancies (HM) patients in China. This study aimed to identify heterogeneous profiles of FoP and their associated predictors among Chinese patients with HM. A convenience sample of patients suffering from HM were enrolled from March 2023 to February 2024. To gather multidimensional data from the Fear of Progression Questionnaire-Short Form (

Совпадение в полном тексте источника
… The world health organization classification of hematological malignancies report of the clinical advisory committee meeting, airlie house, Virginia, November 1997. Mod. Pathol. 13 , 193–207. 10.1038/modpathol.3880035 (2000). 2. Zheng, R. S. et al. Cancer incidence and mortality in China, 2022. …

Development of a Patient-Centered Preference Tool for Patients With Hematologic Malignancies: Protocol for a Mixed Methods Study.

BackgroundThe approval of novel therapies for patients diagnosed with hematologic malignancies have improved survival outcomes but increased the challenge of aligning chemotherapy choices with patient preferences. We previously developed paper versions of a discrete choice experiment (DCE) and a best-worst scaling (BWS) instrument to quantify the treatment outcome preferences of patients with hematologic malignancies to inform shared decision making.ObjectiveWe aim to develop an electronic health care tool (EHT) to guide clinical decision making that uses either a BWS or DCE instrument to capt

Совпадение в полном тексте источника
… Bisel Endowed Young Investigator Award from the Conquer Cancer Foundation, Alexandria, Virginia (principal investigator: DRR). The project described was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant award number UL1TR002489. …

Desensitization: Overcoming the Immunologic Barriers to Transplantation.

HLA (Human Leucocyte Antigen) sensitization is a significant barrier to successful kidney transplantation. It often translates into difficult crossmatch before transplant and increased risk of acute and chronic antibody mediated rejection after transplant. Over the last decade, several immunomodulatory therapies have emerged allowing for increased access to kidney transplantation for the immunologically disadvantaged group of HLA sensitized end stage kidney disease patients. These include IgG inactivating agents, anti-cytokine antibodies, costimulatory molecule blockers, complement inhibitors,

Совпадение в полном тексте источника
… graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization Transplantation 2015 99 7 1423 1430 10.1097/tp.0000000000000525 2-s2.0-84940722141 25606792 5 Organ Procurement and Transplantation Network Analysis Shows Kidney Allocation System Achieving Goals 2016 Virginia …

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Brigham and Women's Hospital, Boston, USA 3 University of Washington, Washington, USA 4 University of Texas Southwestern Medical Center, Dallas, USA 5 SUNY Downstate Medical Center, New York, USA 6 Hospital for Special Surgery, New York, USA 7 Lenox Hill Hospital, New York, USA 8 University of Virginia … A025: Multicenter evaluation of the effect of surgical approach on sagittal plane alignment in one- or two- level fusions for degenerative pathology Jean-Christophe Leveque 1 , Caroline Drolet 1 , Venu Nemani 1 , Katie Krause 1 , Alia Rathiore 2 , Younus Baig 2 , and Philip Louie 1 1 Neurosurgery, Virginia …

Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.

Background and aimsAccurate differentiation of cardiac amyloidosis (CA) from phenotypic mimics remains challenging using current clinical and echocardiographic techniques. The accuracy of a novel artificial intelligence (AI) screening algorithm for echocardiography-based CA detection was assessed.MethodsUtilizing a multisite, multiethnic dataset (n = 2612, 52% CA), a convolutional neural network was trained to differentiate CA from phenotypic controls using transthoracic apical four-chamber video clips. External validation was conducted globally across 18 sites including 597 CA cases and 2122

Совпадение в полном тексте источника
… Amit R Patel, Division of Cardiovascular Medicine, University of Virginia Medical Center, 1215 Lee Street, PO Box Charlottesville, VA 800158, USA. Karima Addetia, University of Chicago, Chicago, IL, 5758 South Maryland Avenue, M.C. 9067, Chicago, IL 60637, USA. …

Are We Ready For "Triplet" Therapy in Higher-Risk MDS?

Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain the only disease-modifying therapies, and are palliative in nature. Recent interest has grown in extending combination chemotherapies used to treat acute myeloid leukemia (AML) to patients with MDS, including novel combination chemotherapy "doublets" and "triplets." In this review, we discuss consi

Совпадение в полном тексте источника
… Klimek Virginia M. Santos Fabio P. S. Boultwood Jacqueline Kotsianidis Ioannis Santini Valeria Solé Francesc Platzbecker Uwe Heuser Michael Valent Peter Ohyashiki Kazuma Finelli Carlo Voso Maria Teresa Shih Lee-Yung Fontenay Michaela Jansen Joop H. Cervera José Gattermann Norbert Ebert Benjamin L. …

Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades.

Carbapenem-nonsusceptible Citrobacter spp. (CNSC) are increasingly recognized as health care-associated pathogens. Information regarding their clinical epidemiology, genetic diversity, and mechanisms of carbapenem resistance is lacking. We examined microbiology records of adult patients at the University of Pittsburgh Medical Center (UMPC) Presbyterian Hospital (PUH) from 2000 to 2018 for CNSC, as defined by ertapenem nonsusceptibility. Over this time frame, the proportion of CNSC increased from 4% to 10% (P = 0.03), as did daily defined carbapenem doses/1,000 patient days (6.52 to 34.5; R2 =

Совпадение в полном тексте источника
… These plasmids were also highly similar to the pCAV1193-166 plasmid found in a bla KPC -carrying K. pneumoniae isolate from Virginia ( Fig. 4A ) ( 42 ). …

Rotating Nightshift Work and Hematopoietic Cancer Risk in US Female Nurses.

BACKGROUND: Nightshift work is a plausible risk factor for hematologic cancer, but epidemiological evidence remains sparse, especially for individual subtypes. We prospectively examined the association of rotating nightshift work with hematopoietic cancer risk. METHODS: This cohort study included US women from the Nurses' Health Study (NHS: n = 76 846, 1988-2012) and Nurses' Health Study II (NHSII: n = 113 087, 1989-2013). Rotating nightshift work duration was assessed at baseline (both cohorts) and cumulatively updated (NHSII). Cox regression was used to estimate hazard ratios (HRs) and 95%

Совпадение в полном тексте источника
… World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835–3849. 51. Tang YL, Sun X, Huang LB, et al. …

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective.

Anemia is common in patients with cancer or with chronic kidney disease (CKD). Although the introduction of erythropoiesis-stimulating agents (ESAs) has transformed the management of anemia, their use has been complicated by a number of factors including frequent guideline updates, safety concerns and, in the United States, a Risk Evaluation and Mitigation Strategy (REMS) program, which aimed to ensure that the benefits of ESAs outweigh the risks. Many previous concerns around ESA use in cancer and CKD have been addressed by the reassuring results of post-approval studies, and biosimilar ESAs

Совпадение в полном тексте источника
… Thesis, Graduate School, Virginia Commonwealth University, Richmond, VA: 10.1016/j.jval.2013.03.614 Singh A. K., Szczech L., Tang K. L., Barnhart H., Sapp S., Wolfson M., et al. (2006). Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. …

Резюме книги: ISEV2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… OT4.01 Terminal complement components are critical in the release of cellular RNA in circulation Virginia Camacho 1,2 , John Tigges 1 , Shulin Lu 1 , Thomas Thomou 1 , Vasilis Toxavidis 1 , Horea Rus 3 and Ionita C. …

Selected abstracts from the XXXVIII National Congress of the Italian Society of Hypertension (SIIA)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.